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Capsaicin cough sensitivity increases during upper 
respiratory infection 
F. O’CONNELL*, V. E. THOMAS*, J. M. STUDHAM”, N. B. PRIDE? AND R. W. FULLERS 
Departments of *Clinical Pharmacology and TMedicine, Royal Postgraduate Medical School, 
London, U.K. 
The mechanism of cough associated with upper respiratory infection (URI) is poorly understood. This paper 
reports a study of the role of altered sensitivity of capsaicin-sensitive airway nerves. 
In a prospective study, baseline (B) capsaicin-induced cough and methacholine-induced airway responsive- 
ness were measured in 103 healthy volunteers. During the following year, 31 subjects reattended for challenge 
testing during URI (I) and after recovery (R). 
The log concentration of capsaicin required to elicit two coughs (C2) was significantly lower during 
infection than recovery but not baseline [median (interquartile range) B=0.59 (0.28-1.20), 1=0.27 (O-0.89) 
Rx0.89 (0.2%1.49)]. Log C5 (concentration causing five coughs) was lower during infection than baseline and 
recovery [B=1.79 (1.20-2.70), 1=1.49 (0.89-2.08), R= 1.79 (1.20-2.40)]. FEV, and PC,, methacholine values 
were unchanged during infection compared to baseline. Subjects with dry cough (n = 14) had lower C5 values 
during infection than both baseline and recovery, and lower C2 values during infection than recovery; in these 
subjects, increase in capsaicin sensitivity correlated with cough severity score. Subjects with productive cough 
or no cough showed no consistent changes during infection. Twenty-six control subjects who reattended 
without URI showed no change in capsaicin sensitivity. 
Upper respiratory infection may cause cough as a result of increased sensitivity of capsaicin-sensitive 
afferent airway nerves without affecting airway calibre or responsiveness. 
Introduction 
Upper respiratory infection (URI) is frequently 
accompanied by cough (1,2). It is surprising that only 
one study has reported measurements of cough sen- 
sitivity to an inhaled tussigen during URI. Empey 
et al. showed that during URI in normal healthy 
volunteers, cough sensitivity to inhaled citric acid is 
temporarily increased, suggesting that cough is due 
to increased sensitivity of rapidly adapting receptors 
secondary to virus-induced airway inflammation (3). 
However, the study was not prospective. Curley et al. 
have suggested that post-nasal drip is responsible for 
cough during URI, but did not measure cough 
sensitivity so the role of afferent cough nerves could 
not be assessed (1). Patients with persistent dry cough 
due to asthma, gastro-oesophageal reflux (GOR), 
ACE inhibitors or unidentifiable cause (chronic 
‘idiopathic’ cough) show enhanced cough sensitivity 
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to inhaled capsaicin compared to normal healthy 
individuals, patients with chronic cough due to post- 
nasal drip, asthmatics without cough and patients 
with productive cough due to chronic bronchitis or 
bronchiectasis (46). Many patients with chronic 
idiopathic cough give a convincing past history of 
URI at the onset of their cough suggesting that URI 
may play a part in the pathogenesis of this type of 
cough. Furthermore, inhalation of PGE, (7) and 
PGF,, (8) in normal individuals leads to enhance- 
ment of the cough response to inhaled capsaicin 
suggesting that the presence of inflammatory media- 
tors in the airways may lead to enhanced sensitivity 
of capsaicin-sensitive afferent airway nerves. Whether 
this is the predominant mechanism responsible for 
cough during URI is not known. 
In this study, the effects of uncomplicated URI on 
cough sensitivity using inhaled capsaicin (9) was 
assessed prospectively in normal healthy volunteers. 
The relationship between changes in cough sensitivity 
to inhaled capsaicin, perceived symptoms (particu- 
larly cough) and changes in airway responsiveness to 
inhaled methacholine were also studied. 
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Table 1 Symptom prevalence and total symptom scores 
No. (%) of subjects 
Symptom 
Illness 
(n=31) 
Dry Productive 
(n= 14) (n=8) 
No. 
(n=9) 
Cough 
Runny nose 
Watery nasal secretions 
Thick nasal secretions 
Blocked/stuffy nose 
Sneezing 
Sore throat 
Hoarseness 
Post-nasal drip 
Phlegm 
Wheeze 
Shortness of breath 
Sinus pain 
Facial pain 
Ear pain 
Dizziness 
Headache 
Malaise 
Myalgia 
Fever 
Chills 
Median (IQR) 
Total symptom score 
22 (71) 
26 (84) 
23 (74) 
9 (29) 
24 (77) 
21 (68) 
23 (74) 
12 (39) 
12 (39) 
13 (42) 
5 (16) 
4 (13) 
8 (26) 
6 (19) 
7 (23) 
1 (3) 
13 (42) 
14 (45) 
13 (42) 
9 (29) 
10 (32) 
12 (9-18) 
14 (100) 
12 (86) 
11 (79) 
4 (29) 
9 (64) 
10 (71) 
13 (93) 
6 (43) 
8 (57) 
0 (0) 
0 (0) 
1 (7) 
3 (21) 
2 (14) 
4 (29) 
1 (7) 
4 (29) 
5 (36) 
5 (36) 
3 (21) 
3 (21) 
13 (8-18) 
8 (100) 
5 (63) 
4 (50) 
4 (50) 
7 (88) 
4 (50) 
6 (75) 
5 (63) 
3 (38) 
8 (100) 
4 (50) 
3 (38) 
2 (25) 
1 (13) 
2 (25) 
0 (0) 
5 (63) 
7 (88) 
5 (63) 
4 (50) 
5 (63) 
18 (11-26) 
0 (0) 
9 (100) 
8 (89) 
1 (11) 
8 (89) 
7 (78) 
4 (44) 
1 (11) 
1 (11) 
2 (22) 
1 (11) 
0 (0) 
3 (33) 
3 (33) 
1 (11) 
0 (0) 
4 (44) 
2 (22) 
3 (33) 
2 (22) 
2 (22) 
10 (7-15) 
Maximum possible total symptom score=63. 
Subjects and Methods 
The study had approval of the Royal Postgraduate 
Medical School and Hammersmith Hospital 
Research Ethics Committee and all subjects gave 
their written informed consent. One hundred and 
three healthy volunteers aged over 18 years were 
recruited over a 1-yr period according to the follow- 
ing exclusion criteria: pregnancy or lactation; URI 
within 6 weeks; pre-existing systemic disease which 
might compromise the safety of capsaicin or metha- 
choline challenge testing, or confound interpretation 
of collected data; history of seasonal rhinitis; asthma 
or atopy; intake of medications (other than oral 
contraceptives). 
All 103 subjects attended when completely well for 
Baseline assessment which included medical history, 
physical examination, and capsaicin and metha- 
choline challenge tests. Subjects who developed 
URI were asked to attend the laboratory for repeat 
challenge tests during their illness and again at least 
4 weeks after complete recovery. They were also 
asked to complete a symptom diary by attributing a 
daily severity score from &3 (O=none, l=mild, 
2=moderate, 3=severe) throughout their illness 
(each evening) to each of 13 symptoms: sneezing, 
blocked/stuffy nose, runny nose, cough, phlegm/ 
sputum, sore throat, hoarseness, sinus/facial pain, ear 
pain, headache, fever, chills, muscle aches. A labora- 
tory questionnaire was used at the Illness assessment 
to elucidate symptom severity at the time of challenge 
testing (Table 1). Cough was classified as dry or 
productive and a series of questions designed to 
attribute a cough severity score from O-12 were asked 
(10). A randomly selected control group (n=26) 
drawn from the 72 subjects who did not develop URI 
were asked to attend the laboratory for repeat 
capsaicin challenge testing 6-18 months after their 
Baseline visit. 
CAPSAICIN COUGH CHALLENGE 
Capsaicin (Sigma, U.K.) stock solution (10 mM in 
absolute alcohol) was diluted in a hydroalcoholic 
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solution (30% alcohol) to give a 1 mM capsaicin 
solution. This was further diluted with normal saline 
to give doubling concentrations from 0.5-500 PM. At 
1-min intervals, subjects inhaled from just below 
functional residual capacity (FRC), a single breath 
of saline or capsaicin from a nebulizer attached to 
a breath-activated dosimeter (PK Morgan Ltd., 
Gillingham, Kent, U.K.). The output from a single 
l-s breath of this nebulizeddosimeter was 5-7 ~1 and 
the mass median diameter of the aerosol was 3.5- 
4 pm. Breaths of capsaicin were alternated at random 
with breaths of saline to minimize the risk of con- 
ditioned responses and, between breaths, subjects 
continued to breathe room air. The number of 
coughs in response to each concentration (over the 
1-min period immediately after each breath of cap- 
saicin) was recorded by the investigator, and the 
challenge was stopped when the concentration which 
elicited five or more coughs (C5) was reached or the 
highest concentration (500 ,UM) had been adminis- 
tered. The lowest concentrations of capsaicin which 
elicited at least two (C2) and five (C5) coughs were 
derived for each challenge. Where a subject did not 
cough at least five times after inhalation of the 
highest concentration actually used (~OO~M), a C5 
value of 1000 ,UM was assumed. Reproducibility of C2 
in the authors’ laboratory is I 1 doubling dilution in 
95% of subjects and of C5 is I 1 doubling dilution in 
76% of subjects. 
METHACHOLINE CHALLENGE 
Methacholine (Sigma, U.K.) was dissolved in 
normal saline to make doubling concentrations 
from l-64 mg ml- I. Methacholine bronchial chal- 
lenge was performed by a method based on that of 
Chai et al. (11). Forced expiratory volume in 1 s 
(FEV,) was measured using a dry spirometer (Vital- 
lograph). Baseline values were compared to pre- 
dicted values (12). Subjects inhaled, starting from 
just below FRC, five breaths of normal saline with 
a 5-s breath hold after each inhalation. FEV, was 
measured 1 min after the last breath of saline. 
Subjects then inhaled, in the same fashion, five 
breaths of doubling concentrations of methacholine 
with measurement of FEV, 1 min after the last 
breath of each concentration. The challenge was 
stopped when a 15% fall in FEV, had been 
achieved or the highest concentration of metha- 
choline had been administered. The predicted con- 
centration of methacholine which would have 
caused a 15% fall in FEV, compared to saline 
(PC,,) was calculated by interpolation from the log 
concentration-response curve. Where no 15% fall 
was achieved, a PC,, of 65 mg ml - ’ was assumed. 
STATISTICAL ANALYSIS 
For each subject who attended during illness, a 
total symptom score was calculated by addition of 
the severity scores for the individual symptoms on 
the laboratory questionnaire. Total symptom scores 
on the day of Illness assessment were compared 
between subjects with dry, productive and no cough 
by the Mann-Whitney test. In a similar fashion, the 
total daily symptom score was calculated from the 
symptom diary data. This enabled assessment of 
the duration and overall severity of illness, and the 
peak day of illness for each subject. 
Log C2 and C5 values and log PC,, values were 
right-censored in significant number of challenges; 
that is, the desired response was not achieved with 
the maximum concentration administered. Therefore, 
rank tests and parametric tests were considered 
inappropriate and these data were compared between 
visits by the Sign test for non-parametric data, using 
a Bonferroni procedure to correct for multiple com- 
parisons (13). Power calculations based on this 
method of comparison determined that 30 subjects 
with illness were required to detect a difference 
between visits and the principal analysis carried out 
was a comparison between the three visits for the 
complete Illness group. A secondary similar analysis 
was carried out within the subgroups with dry, 
productive and no cough to assess whether any 
difference detected in the main analysis could be 
attributed to a particular subgroup. 
Changes in log PC,,, log C2 and log C5 from 
Baseline visit to Illness visit were calculated for each 
subject. Kendall Rank Correlation coefficients were 
calculated for A log PC,,, total symptom and cough 
severity scores vs. A log C2 (and A log C5) to assess 
the correlation between changes in bronchical 
responsiveness to methacholine and symptoms, and 
changes in cough sensitivity to capsaicin. Again, a 
Bonferroni procedure was used to correct for 
multiple comparisons. 
Results 
One hundred and three subjects were recruited to 
the study. Median [interquartile range (IQR)] log C2 
and log C5 values at Baseline assessment were 0.59 
(0.28-1.20) and 1.49 (0.89-2.40) pM capsaicin respec- 
tively. Mean (95% CI) baseline FEV, was 102 & 3.3% 
of predicted. Only 25 subjects achieved a PC,, 
< 64 mg ml ~ ’ methacholine. 
Thirty-one subjects reattended during their next 
URI for Illness assessment and again at least 4 weeks 
after complete recovery for Recovery assessment. 
Fourteen complained of dry cough, eight complained 
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Table 2 Demographic data 
Group or subgroup 
(no. of subjects) 
Mean (range) 
age (years) 
No. (%) of 
females 
Median (range) days from 
onset of illness to illness 
challenge testing 
Illness (n = 3 1) 
Dry cough (n = 14) 
Productive cough (n=S) 
No cough (n=9) 
Control (n=26) 
32(20-58) 24 (77) 5 (2-10) 
32 (20-54) 12 (86) 5 (2-9) 
34(23-58) 5 (62) 5 (3-10) 
29 (2CL46) 7 (78) 4 (3-6) 
31 (21-68) 20 (77) 
of productive cough and nine had no cough during Median (IQR) total symptom score was 18 (1 l-26) in 
illness. Twenty-six randomly selected control subjects the subgroup with productive cough compared to 10 
who had not suffered URI attended for repeat (7-15) in the subgroup with no cough (P<O.O5). 
capsaicin cough challenge 6-18 months after Baseline Median (IQR) total symptom score in the subgroup 
assessment. The Illness and Control groups were well with dry cough was 13 (8-18) which was not signifi- 
matched for age and sex as were the Illness subgroups cantly different from either of the other two 
with dry, productive and no cough (Table 2). subgroups. 
SYMPTOM DIARY DATA (COURSE OF ILLNESS) 
CAPSAICIN COUGH CHALLENGE DATA 
Symptom diaries were returned by 29 subjects. The 
median (range) duration of illness was 9 (3-29) days. 
Subjects who complained of cough had longer ill- 
nesses than those without cough and cough was 
invariably the last symptom to clear. Seventeen (59%) 
subjects had mild illness with peak total symptom 
score I 10 (maximum possible score=39). Seven 
(24%) subjects had moderately severe illness with 
peak total symptom score between 11 and 20, and 
five (17%) subjects scored over 20 indicating severe 
illness. Twenty-six (90%) subjects recorded their peak 
total daily symptom score within 5 days of the onset 
of illness and 24 (83%) subjects attended for Illness 
challenge tests within 3 days of their peak total daily 
symptom score. 
LABORATORY QUESTIONNAIRE DATA (DAY OF 
LABORATORY VISIT) 
The number (%) of subjects in the Illness group as 
a whole and in the subgroups with dry, productive 
and no cough who complained of each of the symp- 
toms on the laboratory questionnaire and the median 
(IQR) total symptom scores are shown in Table 1. 
Twenty-six (84%) subjects complained of rhinor- 
rhoea, 24 (77%) had nasal obstruction, 21 (68%) 
sneezing and 23 (74%) sore throat. Constitutional 
symptoms such as fever, malaise, myalgia, chills and 
headache occurred in less than 50% of subjects. 
Post-nasal drip occurred in eight of 14 subjects with 
dry cough, three of eight subjects with productive 
cough, but only one of nine subjects with no cough. 
For the complete Illness group of 31 subjects, log 
C2 values were significantly lower at the Illness visit 
[median (IQR)=0.27 (O-0.89)] compared to the 
Recovery visit [0.89 (0.2881.49), P=O.O06] but not the 
Baseline [0.59 (0.28-1.20), P=O.33] visit. Log C5 
values were significantly lower at the Illness visit [ 1.49 
(0.89-2.08)] compared to both Baseline [1.79 (1.20- 
2.70, P=O.O2] and Recovery [1.79 (1.20-2.40), 
P=O.O015] visits. For the subgroup of 14 subjects 
with dry cough, log C2 values were significantly 
lower during Illness compared to Recovery (P=O.O3) 
but not Baseline values (P=O.12) (Fig. 1). Log C5 
values were lower during Illness compared to Base- 
line and Recovery (P=O.O27 and 0.009 respectively). 
In this subgroup, significant correlation was found 
between cough symptom severity and fall in log C5 
(s=O.44, P=O.O2) but not log C2 (Fig. 2). For the 
subgroups with productive cough and with no cough, 
there were no differences between the three visits for 
log C2 or log C5 values. There no differences between 
Baseline and Recovery for log C2 or C5 for the 
complete group or any of the three subgroups, nor 
were there any significant differences between the 
Baseline (B) and Repeat (R) visits for log C2 or 
log C5 in the 26 control subjects [log C2, Bz0.59 
(0.28489), R=0.59 (0.28-0.89) P=O.26; log C5, 
B=1.20 (0.59-2.08), R=1.49 (1.20-2.10), P=O.21]. 
Also, Baseline and Repeat log C2 and C5 values in 
the Control group were almost identical to those 
of the 46 subjects who attended only for Baseline 
study. 
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Fig. I Log concentration of capsaicin required to elicit at least two (C2) and five (C5) coughs in subjects with (a) dry cough 
(v); (b) productive cough (A); and (c) no cough (0). Horizontal bars represent median values. In subjects with dry cough, 
log CS values were significantly lower during Illness compared to Baseline and Recovery values. Log C2 values were lower 
during Illness compared to Recovery but not Baseline values. The subgroups with productive cough and with no cough 
showed no significant changes during illness. 
FEVl AND METHACHOLINE CHALLENGE DATA subjects (five with dry cough, one with productive 
In the complete Illness group, mean (95% CI) cough and four with no cough) achieved a 
FEV, was 103 (4.1)% predicted at the Baseline visit PC,, < 64 mg ml - ’ methacholine at either the Base- 
and 103 (3.3)% predicted at the Illness visit. Only 10 line or Illness visit or both. There were no significant 
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-0.3 c 
Cough severity score (O-12) 
Fig. 2 Correlation between fall in log C5 and cough 
severity score during illness in 14 subjects with dry cough. A 
significant correlation was found between the fall in log C5 
from Baseline to Illness and cough severity score during 
illness in the subgroup with dr; cough. Kendall Rank 
Correlation Coefficient sxO.44. PzO.02. 
differences between the two visits for the complete 
group or any of the subgroups with dry, productive 
and no cough. 
Discussion 
This prospective study has shown that a temporary 
increase in cough sensitivity to inhaled capsaicin 
develops during URI without any concurrent decline 
in FEV, or increase in airway responsiveness to 
methacholine. The increased capsaicin sensitivity in 
the group who developed URI was largely due to 
consistent increases in subjects who developed dry 
cough; in these subjects, the extent of increase in 
cough sensitivity was related to the severity of cough. 
Eleven of 14 subjects who developed dry cough 
during Illness had a decrease in C5 compared to 
Baseline, and 13 subjects had an increase in C5 on 
Recovery compared to Illness. Some other subjects 
who did not develop cough also showed enhanced 
cough sensitivity to capsaicin during URI compared 
to Baseline and Recovery values. There are several 
possible reasons why cough did not occur in these 
subjects. Compared to the subgroup who developed 
dry cough, they had milder illness, lower total symp- 
tom scores and considerably higher baseline C5 
values so they may not have crossed a threshold for 
development of cough. While there is considerable 
inter-subject variability in cough sensitivity to 
inhaled capsaicin, subjects with dry cough (due to 
ACE inhibitor therapy, GOR, cough variant asthma 
or chronic idiopathic cough) have enhanced cough 
sensitivity to inhaled capsaicin compared to normal 
individuals without cough (5,6) and it may be that a 
cough sensitivity threshold exists for any individual 
below which the symptom cough will not occur. It is 
also possible that different groups of viruses with 
varying ability to induce epithelial damage were 
responsible for illness in the three subgroups (14,15). 
Over the 1-yr study period, no epidemics of influenza 
occurred, and although viral isolation was not 
attempted, it is likely that a heterogenous group of 
viruses were responsible for the observed illnesses. 
Presumably the development of dry cough during 
URI in an individual depends on the interaction 
between the pre-existing cough sensitivity of the 
individual and the ability of the particular respiratory 
virus to enhance that sensitivity beyond a threshold 
at which cough will occur. 
The mechanism of enhancement of capsaicin sen- 
sitivity during uncomplicated URI is of considerable 
interest. Empey et al. demonstrated that the cough 
threshold to inhaled citric acid was lower during URI 
than on recovery in 16 normal subjects (3). Although 
these subjects also showed enhanced bronchial 
responsiveness to inhaled histamine during URI, the 
exaggerated cough response was not blocked by a 
&adrenergic agonist suggesting that alteration in 
bronchial tone was not responsible. They suggested 
that rapidly adapting receptors were sensitized by 
acute virus-induced airway inflammation. In the 
present study, the Baseline study population did not 
have any underlying tendency to airway obstruction 
or airway hyper-responsiveness and no changes were 
detected during illness. Twenty-one of the 31 Illness 
subjects did not achieve a PC,, ~64 mg ml-’ 
methacholine at either the Baseline or Illness visit. It 
is most unlikely, therefore, that the enhanced cough 
sensitivity to inhaled capsaicin during URI was in 
any way related to alteration in bronchial tone or 
airway responsiveness. 
Previous studies of airway responsiveness during 
URI have shown variable results. Bronchial respon- 
siveness to methacholine has been shown to be 
increased in normal healthy subjects with influenza A 
(16) and respiratory syncytial virus (17) infection but 
not with experimental Rhinovirus infection (14,18). 
Similarly, airway responsiveness to inhaled histamine 
has been shown to be increased in normal subjects 
with naturally occurring URI (3) but not in normal 
subjects or mild asthmatics with experimental rhino- 
virus infection (14,19). Multiple factors are involved 
in determining development of airway hyper- 
responsiveness during URI, including age, sex, the 
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infecting micro-organism, severity of symptoms and 
presence of pre-existing airway hyper-responsiveness 
(20). The current study provides strong evidence that 
increased sensitivity of capsaicin-sensitive airway 
nerves may occur during URI independent of any 
alteration in airway responsiveness. 
Within the subgroup with productive cough, 
changes in cough sensitivity during URI were in- 
consistent. Subjects with productive cough were 
heterogeneous in terms of quantity of secretions 
produced, type of secretions produced (serous, 
mucoid or mucopurulent) and source of secretions 
(bronchial or nasal with post-nasal drip). The 
changes in capsaicin sensitivity in thee subjects can 
not be clarified further with currently available data. 
The results of this study may be of relevance not 
only to acute URI in healthy individuals but may 
have implications for understanding of other con- 
ditions involving cough in which the cough response 
to inhaled capsaicin is increased (43). In cough- 
variant asthma, this is presumably secondary to the 
presence of inflammatory mediators released during 
airway inflammation. Recent studies suggest that 
GOR-induced cough may occur with reflux into the 
lower oesophagus alone, suggesting that acid-induced 
damage to lower oesophageal epithelium may cause 
sensitization of receptors here which may mediate 
cough (21). The pathogenesis of chronic idiopathic 
cough (chronic dry cough not due to asthma, GOR, 
post-nasal drip, drug therapy or other identifiable 
cause) is poorly understood. As a group, however, 
these patients show enhanced cough sensitivity to 
inhaled capsaicin compared to normal non-coughers, 
again suggesting that sensory cough receptors 
have become over-sensitized (4,5). While the cause 
of this is unclear, many such patients give a con- 
vincing history of URI at the onset of the cough and 
it is possible that sensitization of cough receptors 
which occurs during URI becomes persistent or 
self-perpetuating in these patients. Further studies 
in this group of patients may lead to better under- 
standing of the pathogenesis of chronic idiopathic 
cough. 
This study shows that cough sensitivity to inhaled 
capsaicin is enhanced in subjects who develop dry 
cough during URI in the absence of changes in 
bronchial tone or airway responsiveness. A possible 
mechanism is that virus-induced airway inflam- 
mation an&or associated inflammatory mediators 
sensitize airway receptors involved in mediation of 
cough. Further studies may elucidate more precisely 
the mechanisms by which the sensitivity of afferent 
airway nerves is enhanced leading to dry cough 
during URI. 
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